-
Stone Energy Corporation (NYSE: SGY) shares surged
16.7 percent to $14.07. Stone Energy shares have dropped 88.55 percent over the past 52 weeks, while the S&P 500 index has
gained 1.45 percent in the same period.
-
Aldeyra Therapeutics Inc (NASDAQ: ALDX) shares
jumped 12.7 percent to $6.41. Stifel Nicolaus initiated coverage of Aldeyra Therapeutics with a Buy rating.
-
AEterna Zentaris Inc. (USA) (NASDAQ: AEZS) shares
climbed 12.3 percent to $3.66 as the company reported that it has signed an exclusive license agreement with Cyntec, an
affiliate of Orient EuroPharma Co, for Zoptrex.
-
Kinross Gold Corporation (USA) (NYSE: KGC) gained
6.8 percent to $5.22. Macquarie upgraded Kinross Gold from Underperform to Neutral.
-
Thor Industries, Inc. (NYSE: THO) shares gained 6.6
percent to $69.04 after the company disclosed the acquisition of Jayco, Corp. for about $576 million in cash.
-
Mesoblast limited (ADR) (NASDAQ: MESO) shares
rose 5.6 percent to $4.21 after the company issued an update on heart failure trial and funding of clinical operations.
Mesoblast projects to do interim analysis for Phase 3 endpoints in Q1 2017
-
Netflix, Inc. (NASDAQ: NFLX) gained 5.5 percent
to $96.45. Canaccord Genuity initiated coverage on Netflix with a Buy rating and a $120.00 price target.
-
Harmony Gold Mining Co. (ADR) (NYSE: HMY) rose 5.3
percent to $3.80. Macquarie upgraded Harmony Gold Mining from Underperform to Neutral.
-
Pan American Silver Corp. (USA) (NASDAQ: PAAS)
shares gained 4.4 percent to $17.17. Silver futures gained 4.6 percent to trade at $19.49 an ounce.
-
Randgold Resources Ltd. (ADR) (NASDAQ: GOLD)
gained 4.3 percent to $116.78. Macquarie upgraded Randgold from Neutral to Outperform. Gold futures gained 1.4 percent to
$1,338.90 an ounce.
-
Galectin Therapeutics Inc (NASDAQ: GALT) shares
rose 3.4 percent to $1.52. Roth Capital assumed Galectin Therapeutics with a Buy rating.
-
Array Biopharma Inc (NASDAQ: ARRY) shares rose
3.1 percent to $3.67 after the company reported the submission of NDA for binimetinib to the FDA.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.